Skip to content
PeptideAI
Anecdotalblood sugargut healthlongevity

Suprefort

Pancreas peptide extract in capsule form, taken in monthly courses for glycaemic and digestive-enzyme support, usually by people with prediabetes or insulin resistance.

Also known as A-1, pancreas Cytomax, pancreas peptide bioregulator, Suprefort A-1, Suprefort, Suprefort Lingual, A-1

Anecdotal — Community reports without controlled evidence. Treat the confident dosing charts accordingly.

No controlled human trials, no published glycaemic data. The supporting material is manufacturer literature plus preclinical work on the related synthetic peptide. Anyone presenting this as a treatment for diabetes is well outside the evidence.

How it works

Suprefort is peptide complex A-1, extracted from the pancreas of young calves at 10 mg per capsule. Manufacturer claims cover both arms of pancreatic function: better insulin secretion and glucose handling on the endocrine side, and improved digestive enzyme output on the exocrine side. The synthetic counterpart is Pancragen (Lys-Glu-Asp-Trp), which has cell-culture data on insulin gene expression. Neither has been shown to change fasting glucose, HbA1c, or an oral glucose tolerance test in a human being, and no product of this kind should be understood as a diabetes therapy.

Targets: Pancreatic islets, Exocrine pancreas, Insulin secretion

Dosing

ProtocolDoseFrequencyRoute
Standard capsule course10-15 minutes before a meal.10 mg – 20 mgone to two capsules daily for 10 to 30 daysoral
  • · 10 mg of peptide complex per capsule.

Cycling

Ten to thirty days per course, two to three courses a year.

Work out your exact syringe units →

Pharmacology

Half-life
Not measured after oral dosing.
Onset
Nothing acute. It does not lower blood glucose the way a drug does.
Routes
oral, sublingual
Molecule
Bovine pancreas-derived peptide complex in capsule form

Handling

Diluent
Not applicable - supplied as oral capsules.
Lyophilised
Not applicable - store capsules cool, dry and out of direct sunlight.
Reconstituted
Not applicable.
Light sensitive
Yes — keep it out of the light

Mixing

Nothing to reconstitute.

Side effects

  • uncommonMild digestive upset— Often excipient-related.
  • rareAllergic reaction to bovine protein— Animal-tissue-derived product.

Do not use if

  • Type 1 diabetes - never reduce insulin on the basis of a bioregulator course. This is the single most dangerous misuse in the category.
  • Known bovine protein allergy.
  • Pregnancy and breastfeeding - no data.
  • Pancreatic malignancy or a history of acute pancreatitis without a clear diagnosis.

Combining it

  • redundantpancragen — Pancragen is the synthetic pancreas-directed Cytogen; overlapping claims.
  • cautionmetformin — No known interaction, but combining them makes it impossible to attribute any glycaemic change - and metformin is the one with outcome data.
  • cautioninsulin — No evidence it changes insulin requirements; monitor glucose properly regardless.

What to monitor

  • · Fasting glucose and HbA1c before and about three months after a course.
  • · Continuous glucose monitoring if you have one - it will show you honestly whether anything changed.

Legal status

Sold as a food supplement in Russia and much of Europe; imported elsewhere as a dietary supplement. Not an approved drug.

References

  • Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)

Mechanism in depth

No primary literature exists for Suprefort under this name. What gives this particular capsule more standing than the rest of the Cytomax line is what sits next to it: Pancragen, the synthetic counterpart, has both a coherent molecular story - upregulation of Pdx1, Ptf1a, Pax6, Pax4, Foxa2 and Nkx2.2 in aged pancreatic cultures - and a 63-person human study from the Kiev Institute of Gerontology reporting reduced fasting glucose, improved glucose tolerance, lower plasma insulin and a lower insulin resistance index in elderly type 2 diabetics. That is the only human metabolic dataset anywhere in this class. It belongs to the synthetic tetrapeptide, not to this capsule, and the transfer is not legitimate - but it does mean the underlying claim has been tested in people at least once, which is more than can be said for the vascular, hepatic, retinal or cartilage sub-lines. The study's own thesis is also worth carrying across: it framed insulin resistance in the elderly as downstream of a 70 percent nocturnal melatonin deficit, which makes the pineal compounds the more mechanistically interesting purchase for that particular problem.

What usually goes wrong

The dangerous scenario is a type 1 diabetic, or an insulin-treated type 2, reducing insulin on the theory that a pancreatic bioregulator is restoring islet function. In type 1 the beta cells are destroyed, not silenced, and nothing in this capsule brings them back; the consequence of acting otherwise is ketoacidosis. The second failure is using it for digestive symptoms without testing faecal elastase, which means genuine exocrine insufficiency - or coeliac disease, or bile acid diarrhoea, all treatable - goes undiagnosed. The third is the standard evidence transfer: the Pancragen human study appears in Suprefort marketing, and it was a different molecule.

Bloodwork worth running

MarkerWhenWhy it matters
Fasting glucose and fasting insulin, with HOMA-IR calculatedBaseline and four to six weeks after a course, both fasted twelve hours, same time of morning.The endpoint the related human study actually measured, and the cheapest honest test of whether anything is happening. HOMA-IR from a paired fasting draw tells you far more than glucose alone.Act if: Fasting insulin under about 6 mIU/L and HOMA-IR under 1.5 means there is no insulin resistance to correct. Fasting glucose above 7.0 mmol/L or 126 mg/dL twice is diabetes and needs proper treatment.
HbA1cBaseline and three months after a course. Testing sooner is meaningless.The three-month integrated number, and the one a clinician acts on. It cannot be gamed by a good week.Act if: HbA1c above 6.5 percent means diabetes and means metformin, a GLP-1 agonist or insulin - therapies with outcome data - not a capsule.
Faecal elastase-1Once at baseline if digestive symptoms are the reason you are here.If you are buying this for the exocrine claim - bloating, steatorrhoea, poorly digested food - this single stool test tells you whether you actually have pancreatic exocrine insufficiency, which is a real and specifically treatable diagnosis.Act if: Faecal elastase below 200 mcg/g suggests exocrine insufficiency and below 100 mcg/g is severe. That needs prescription enzyme replacement and a search for the cause, not a peptide.
Continuous glucose monitor, two matched fortnightsTwo weeks before and two weeks starting a month after the course, with diet as constant as you can manage.If you have access to one, it is the most honest measure available and it makes the answer unambiguous within a month.Act if: No change in time-in-range across two matched fortnights means the product did nothing for you.

Pharmacokinetics

Metabolism
Presumed near-complete gastrointestinal proteolysis.
Elimination
Not characterised.

Receptor targets

  • No identified receptor or molecular target — None published

    Nothing has been characterised for this preparation.

  • Islet secretory function and insulin gene expression (claimed)

    The transcription-factor work demonstrating this belongs to Pancragen in cell culture, not to this capsule.

  • Exocrine digestive enzyme output (claimed)

    Manufacturer claim with no supporting study, and mechanistically implausible at 10-20 mg per day. This is not enzyme replacement therapy and cannot function as it.

What to expect, and when

Nothing acute - this does not lower blood glucose the way a drug does, and it would be a different and more dangerous product if it did. Weeks one to four: no perceptible effect. Four to six weeks after a course: the window for a fasting insulin and HOMA-IR retest, matching the design of the related human study. Three months: the earliest HbA1c can say anything. Anyone who reports feeling their blood sugar stabilising on a capsule is feeling something else.

Stacking and comparisons

Suprefort with Pancragen is duplication, and the synthetic is the one with the data. The pairing that follows the published reasoning rather than the marketing is with a pineal compound, since the human study's thesis was that melatonin deficiency drives elderly insulin resistance - though that combination has never been tested either. With metformin or a GLP-1, the rule is attribution: those drugs move glucose by margins nothing here approaches, so any improvement belongs to them. With insulin, the rule is safety: never reduce a dose because a capsule course started. Test, and adjust on numbers.

Against metformin: decades of outcome data, negligible cost, cardiovascular benefit. Against a GLP-1 agonist: HbA1c reductions of 1.5-2.5 percentage points, substantial weight loss and cardiovascular outcome trials in tens of thousands of participants. Against Pancragen: the synthetic has the human study and the transcription-factor work. Against berberine or inositol: both at least have randomised human glycaemic data to argue about. Against exercise and weight loss for insulin resistance: those work, reliably, and the effect size dwarfs anything claimed here.

Rough cost

$70–$200/month. A 20-capsule bottle covers ten to twenty days depending on dose. Indicative pricing for the branded Russian product, not verified against vendor listings in this session.

Genuinely uncertain

  • No indexed primary literature exists for Suprefort under this name.
  • Oral bioavailability of the peptide complex has never been measured.
  • No glycaemic or digestive endpoint has ever been published for this capsule; the human data belongs to the synthetic Pancragen.
  • The exocrine enzyme claim has no supporting study and is mechanistically implausible at this dose.
  • Composition is not published lot by lot.
  • Cost figures are indicative estimates and were not verified against live vendor listings in this session.

Papers